Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD

Cohort 1 (Healthy Subjects) Inclusion Criteria: * Male or female aged 18 to 55 years * FEV1 \> 80% of predicted normal (using the Global Lung Function Initiative GLI 2012 reference values) * Body mass index \> 18 and \< 32 kg/m2 * Female subjects of childbearing potential must not be pregnant, breast feeding or lactating and use, with their partner, a male condom plus an approved method of highly effective birth control method * Female subjects of childbearing potential must have a negative serum or urine pregnancy test at the Screening Visit * Male subjects who are sexually active with a partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent * Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory assessments at the time of screening, as judged by the Investigator * Willing and able to provide written informed consent Exclusion Criteria: * Any condition or abnormality (including medical history, clinical laboratory, ECG, physical examination, or vital sign abnormalities), current or past, that, in the opinion of the Investigator * Lower respiratory tract infection within 6 weeks prior to the Screening Visit * History of malignancy of any organ system, except for localized skin cancers, within 5 years prior to the Screening Visit * Major surgery (requiring general anaesthesi…